OZEMPIC® 1 mg is a once-weekly semaglutide injection indicated for improving glycaemic control in adults with type 2 diabetes, alongside diet and exercise. The 1 mg dosage is a standard maintenance dose for ongoing blood sugar management and continued weight reduction support. It is often selected for patients who have responded well to the 0.5 mg dose and require additional therapeutic benefit.

Key Benefits
• Effective long-term glycaemic control for adults with type 2 diabetes
• Supports meaningful and sustained weight reduction
• Once-weekly dosing for convenient, ongoing management
• Can be used as monotherapy or in combination with other diabetes medications
• Helps lower the risk of major cardiovascular events in appropriate patients (as assessed clinically)

How It Works
Semaglutide, the active ingredient in OZEMPIC®, is a GLP-1 receptor agonist that mimics natural incretin hormones. It increases insulin secretion when blood sugar is high, reduces glucagon release, slows gastric emptying, and decreases appetite. These mechanisms collectively improve glucose regulation and support weight loss.

Ideal Candidates
• Adults with type 2 diabetes who require consistent, long-term glycaemic control
• Patients who have successfully completed the 0.25 mg and 0.5 mg titration phases
• Individuals seeking enhanced metabolic support, including appetite reduction
• Patients needing a stable, maintenance-level weekly injection

Administration
Delivered using a prefilled injection pen, administered subcutaneously once weekly into the abdomen, thigh, or upper arm.
The 1 mg dose is commonly used for extended treatment duration before consideration of escalation to 2 mg, depending on clinical response and tolerance.

Possible Side Effects
Common side effects include nausea, vomiting, diarrhoea, constipation, abdominal discomfort, or decreased appetite, especially during dose escalation. These effects typically improve as treatment continues.
Less common but serious risks include pancreatitis, gallbladder issues, severe gastrointestinal reactions, or allergic responses. Patients should be monitored by a healthcare professional.